Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx, Inc    CDNA

CAREDX, INC

(CDNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 127 M
EBIT 2019 -25,8 M
Net income 2019 -23,8 M
Debt 2019 -
Yield 2019 -
Sales 2020 170 M
EBIT 2020 -12,0 M
Net income 2020 -11,5 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -47,4x
P/E ratio 2020 -97,6x
Capi. / Sales2019 8,90x
Capi. / Sales2020 6,64x
Capitalization 1 132 M
More Financials
Company
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular... 
More about the company
Surperformance© ratings of CareDx, Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CAREDX, INC
02/13CareDx to Report Fourth Quarter and Full Year 2019 Financial Results on Febru..
GL
02/11CareDx's Patent Rights Upheld By Delaware Court
GL
02/04CareDx Launches AiTraC Conference
GL
01/13CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results
GL
01/13CAREDX, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/10CareDx's AlloSeq cfDNA Awarded CE Mark Approval
GL
01/09CareDx Leadership at ASTS Meeting
GL
01/08CareDx's False Advertising Complaint Upheld By Court
GL
2019CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
2019CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients
GL
2019CAREDX : Supports Bipartisan Legislation to Protect Kidney Transplant Patients
AQ
2019CareDx to Participate in Upcoming Investor Conferences
GL
2019CareDx at ASN Kidney Week
GL
2019CareDx Advances Patient Care with AlloSure 3.0
GL
2019CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
More news
News in other languages on CAREDX, INC
2019CAREDX INC : Veröffentlichung des Jahresergebnisses
2019CAREDX INC : publication des résultats annuels
2016CAREDX : Un centre européen de suivi de la greffe cardiaque à Strasbourg
2016CAREDX INC : publication des résultats annuels
More news
Analyst Recommendations on CAREDX, INC
More recommendations
Sector news : Bio Diagnostics & Testing
02/12Coronavirus-Drug Development Becomes a Top Focus at Gilead
DJ
02/12GILEAD SCIENCES : Correction to Report About Gilead Sciences' Work on a Coronavi..
DJ
02/12Gilead Sciences Scrambles to Supply Experimental Coronavirus Drug
DJ
02/11NOVARTIS, INCYTE : Capmatinib Gets FDA Priority Review
DJ
02/10GILEAD SCIENCES : Unit Gets FDA Priority Review for KTE-X19
DJ
More sector news : Bio Diagnostics & Testing
Chart CAREDX, INC
Duration : Period :
CareDx, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX, INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 49,20  $
Last Close Price 26,67  $
Spread / Highest target 136%
Spread / Average Target 84,5%
Spread / Lowest Target 57,5%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chairman & Chief Executive Officer
Reginald Seeto President & Chief Business Officer
Paul Ciccolella Senior Vice President-Global Operations
Michael Bell Chief Financial & Principal Accounting Officer
James P. Yee Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CAREDX, INC23.64%1 132
EXACT SCIENCES CORPORATION6.16%14 455
GUARDANT HEALTH, INC.7.88%7 916
GENSCRIPT BIOTECH CORPORATION1.02%4 338
IOVANCE BIOTHERAPEUTICS, INC.-13.91%3 007
INVITAE CORPORATION67.64%2 610